Mechanism of action

The development approach combines two receptor systems involved in energy metabolism. Zimmermann and colleagues (2022) characterized activity at both receptors in cellular assays and animal models. The experiments examined food intake, gastric emptying, glucose regulation and metabolic processes related to energy use. The peptide carries a fatty-acid modification. This research supports the concept of dual receptor activation, but it does not explain the size of clinical effects on its own. In particular, animal findings cannot establish a separate benefit to the human liver that is independent of body-weight changes. Clinical endpoints need their own evaluation, with the study population and measurement method kept in view.

State of evidence

A phase 2 study published in 2024 examined 387 adults without diabetes over 46 weeks. A separate phase 2 paper assessed histological changes in 293 treated participants with biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH). It reported more frequent MASH improvement without worsening fibrosis than placebo. In 2026, SYNCHRONIZE-1 reported results in 725 adults without diabetes over 76 weeks. Mean body-weight changes were approximately minus 12% to minus 13% in the active groups and minus 5% with placebo under an analysis that accounted for early treatment discontinuation and certain accompanying treatments. SYNCHRONIZE-MASLD studied 216 treated adults with obesity and metabolic fatty liver disease over 48 weeks. It met its coprimary endpoints for body-weight change and reduction in liver fat measured by MRI. Gastrointestinal complaints were common in both phase 3 reports. These trials do not resolve all questions about long-term safety or outcomes such as cardiovascular events. Reduced liver fat is also not direct evidence of preventing cirrhosis. Published phase 3 findings and medicine authorization remain separate questions, and the papers do not establish the clinical suitability of a particular research product.

Questions about the research

Why can one study report different weight-change estimates?

The estimates may answer different statistical questions. An analysis of efficacy under defined treatment conditions differs from an analysis that also considers discontinuation or certain accompanying treatments. Population, duration and analysis approach must accompany the number. Selecting the most favorable estimate alone gives an incomplete account of the findings.

Is reduced liver fat the same as improved fibrosis?

No. Liver fat, inflammatory activity and fibrosis are different features. SYNCHRONIZE-MASLD used MRI-measured liver fat as a coprimary endpoint, whereas the earlier MASH study used biopsies. An imaging change should not be treated as proof of a histological fibrosis benefit or as established prevention of later liver complications.

Are survodutide, retatrutide and tirzepatide interchangeable?

No. Their structures and receptor profiles differ. A shared research area does not demonstrate equivalent effects. The studies discussed here predominantly compare survodutide with placebo and do not establish a general ranking against other peptides. Appropriate direct comparison studies would be needed to address comparative clinical questions.

Sources

1. Zimmermann et al., Mol Metab 2022DOI: 10.1016/j.molmet.2022.101633PMID: 36356832
2. le Roux et al., Lancet Diabetes Endocrinol 2024DOI: 10.1016/S2213-8587(23)00356-XPMID: 38330987
3. Sanyal et al., N Engl J Med 2024DOI: 10.1056/NEJMoa2401755PMID: 38847460
4. le Roux et al., N Engl J Med 2026, SYNCHRONIZE-1DOI: 10.1056/NEJMoa2600751PMID: 42253238
5. Kaplan et al., Nat Med 2026, SYNCHRONIZE-MASLDDOI: 10.1038/s41591-026-04479-3PMID: 42252333

Mechanism of action

The development approach combines two receptor systems involved in energy metabolism. Zimmermann and colleagues (2022) characterized activity at both receptors in cellular assays and animal models. The experiments examined food intake, gastric emptying, glucose regulation and metabolic processes related to energy use. The peptide carries a fatty-acid modification. This research supports the concept of dual receptor activation, but it does not explain the size of clinical effects on its own. In particular, animal findings cannot establish a separate benefit to the human liver that is independent of body-weight changes. Clinical endpoints need their own evaluation, with the study population and measurement method kept in view.

State of evidence

A phase 2 study published in 2024 examined 387 adults without diabetes over 46 weeks. A separate phase 2 paper assessed histological changes in 293 treated participants with biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH). It reported more frequent MASH improvement without worsening fibrosis than placebo. In 2026, SYNCHRONIZE-1 reported results in 725 adults without diabetes over 76 weeks. Mean body-weight changes were approximately minus 12% to minus 13% in the active groups and minus 5% with placebo under an analysis that accounted for early treatment discontinuation and certain accompanying treatments. SYNCHRONIZE-MASLD studied 216 treated adults with obesity and metabolic fatty liver disease over 48 weeks. It met its coprimary endpoints for body-weight change and reduction in liver fat measured by MRI. Gastrointestinal complaints were common in both phase 3 reports. These trials do not resolve all questions about long-term safety or outcomes such as cardiovascular events. Reduced liver fat is also not direct evidence of preventing cirrhosis. Published phase 3 findings and medicine authorization remain separate questions, and the papers do not establish the clinical suitability of a particular research product.

Questions about the research

Why can one study report different weight-change estimates?

The estimates may answer different statistical questions. An analysis of efficacy under defined treatment conditions differs from an analysis that also considers discontinuation or certain accompanying treatments. Population, duration and analysis approach must accompany the number. Selecting the most favorable estimate alone gives an incomplete account of the findings.

Is reduced liver fat the same as improved fibrosis?

No. Liver fat, inflammatory activity and fibrosis are different features. SYNCHRONIZE-MASLD used MRI-measured liver fat as a coprimary endpoint, whereas the earlier MASH study used biopsies. An imaging change should not be treated as proof of a histological fibrosis benefit or as established prevention of later liver complications.

Are survodutide, retatrutide and tirzepatide interchangeable?

No. Their structures and receptor profiles differ. A shared research area does not demonstrate equivalent effects. The studies discussed here predominantly compare survodutide with placebo and do not establish a general ranking against other peptides. Appropriate direct comparison studies would be needed to address comparative clinical questions.

Sources

1. Zimmermann et al., Mol Metab 2022DOI: 10.1016/j.molmet.2022.101633PMID: 36356832
2. le Roux et al., Lancet Diabetes Endocrinol 2024DOI: 10.1016/S2213-8587(23)00356-XPMID: 38330987
3. Sanyal et al., N Engl J Med 2024DOI: 10.1056/NEJMoa2401755PMID: 38847460
4. le Roux et al., N Engl J Med 2026, SYNCHRONIZE-1DOI: 10.1056/NEJMoa2600751PMID: 42253238
5. Kaplan et al., Nat Med 2026, SYNCHRONIZE-MASLDDOI: 10.1038/s41591-026-04479-3PMID: 42252333